The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009.
about
The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements.Interventions for smoking cessation and reduction in individuals with schizophreniaImpact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophreniaUnmet needs in the management of schizophreniaClinical practice guidelines in psychiatry: more confusion than clarity? A critical review and recommendation of a unified guidelineDeep concernEffective Strategies for Nurses Empowering Clients With Schizophrenia: Medication Use as a Tool in Recovery.Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia.Understanding tDCS effects in schizophrenia: a systematic review of clinical data and an integrated computation modeling analysis.The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statementsAripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration.Optimizing psychosocial interventions in first-episode psychosis: current perspectives and future directionsLong-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injectionEffectiveness of amisulpride in Chinese patients with predominantly negative symptoms of schizophrenia: a subanalysis of the ESCAPE study.Mental health services research training for the next generation of leaders in the public health sector: a case study of the UCSF/SFGH Public Psychiatry Fellowship.Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study.The integration of cognitive remediation therapy into the whole psychosocial rehabilitation process: an evidence-based and person-centered approach.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.Randomized clinical trial of cognitive behavioral social skills training for schizophrenia: improvement in functioning and experiential negative symptoms.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.Cognitive Behavioral Therapy for Psychosis - Training Practices and Dissemination in the United States.Detecting potential adverse reactions of sulpiride in schizophrenic patients by prescription sequence symmetry analysisRoutine outcomes monitoring to support improving care for schizophrenia: report from the VA Mental Health QUERI.Best practices: wellness self-management: an adaptation of the illness management and recovery program in New York State.Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophreniaClozapine prescribing in a Canadian outpatient population.A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophreniaWhat's really wrong with cognitive behavioral therapy for psychosis?Polypharmacy with antipsychotic drugs in patients with schizophrenia: trends in multiple health care systems.Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis.Lessons learned in developing community mental health care in North America.Unravelling psychosis: psychosocial epidemiology, mechanism, and meaningA randomized pilot study of MOtiVation and Enhancement (MOVE) Training for negative symptoms in schizophrenia.Quantifying clinical relevance in the treatment of schizophrenia.Enhancing work-focused supports for people with severe mental illnesses in australia.Randomised controlled trial of a digitally assisted low intensity intervention to promote personal recovery in persisting psychosis: SMART-Therapy study protocol.The experience of Greek-Cypriot individuals living with mental illness: preliminary results of a phenomenological study.Peer Supports for Tobacco Cessation for Adults with Serious Mental Illness: A Review of the Literature.The long-term effectiveness of cognitive behavior therapy for psychosis within a routine psychological therapies serviceEpidemiology and Treatment Guidelines of Negative Symptoms in Schizo-phrenia in Central and Eastern Europe: A Literature Review.
P2860
Q22242826-2AAF15E3-EA2E-422F-9197-45CD5D7F0557Q24235017-93274EB9-C9DD-4D5F-932A-D4F7A6AC141BQ24597701-0401FB12-8524-4F9B-BE48-97A4C768227AQ26822917-72647316-529D-455D-B2A4-622AA118396AQ26830411-0E0880ED-2028-46CD-ABF2-78395A88F346Q28751814-E7A645C9-C115-444B-B6C4-8CBB9890BD66Q30276915-81D07B49-F50F-44FA-8862-9F980B45C656Q30382281-BC31CFFD-A93F-48F5-B555-677DE6CD09F5Q30806352-953669A6-9F49-4826-A57E-AD7F530328F2Q33566124-66F1B54B-D8E6-406C-BE0F-82FCD27DC980Q33614458-653F5159-C878-446A-B101-647EBE9C2CF8Q33631663-26784A4D-632B-43A9-A910-663BDFABE55CQ33817737-DF2032DF-F632-435C-938B-D50A0142AE4FQ33879147-6091A487-3F4C-4112-AAF3-3085BE11EAFFQ34090626-5120642D-C3A2-4EE0-9D67-153FA89A10E3Q34254903-4840B789-1AC4-42D3-976B-D9107ABBF723Q34299032-C2654565-C8B0-4EA1-818C-D7974F86639FQ34315836-BCC044EA-D29D-4222-A3A5-0136700F5272Q34572488-73BC4276-5389-4EBB-999F-18A8CDA94D04Q34640811-3691CA4B-C45D-4F97-BF58-42ACC4909F15Q34657151-3252E489-DB75-4844-8266-7211BDA04C50Q34660087-7A1BC4D6-4C8E-43CD-AD0A-55AF42991C7FQ34680925-C3B15621-AD11-4FBD-B191-1735FD953C86Q34914498-15BB024D-40B7-4276-B896-CD371559D243Q35019258-C9420187-8FFD-4C08-A302-BD3E06526232Q35073113-3FE6CADF-98F3-44AD-A72F-DD31FE894196Q35214804-3365B240-67DC-4B91-90D8-1DBFF1F76C65Q35222535-8E2E1C28-B86A-4E37-8520-F31AB9ABB40EQ35608522-6CC70DEF-A48B-495C-B182-459B190AB0B5Q35683821-2EED6CFD-7983-457F-8CD8-35087487A91AQ35698802-2709A86B-1E31-42A5-ADAB-23B0AD979407Q35740664-6C153559-3B4B-4DC4-B546-FBF3FDFB50EBQ35794290-129354AF-2659-4D00-9EF4-060BBCB7D39DQ35819467-AFC3FF5A-8BC2-4557-AC7A-B09FE0F650D8Q36090496-38FF0C4C-B5DA-4B4B-B154-66EC3598E96AQ36125663-36D77998-6377-4158-97A3-E81A32CB7F02Q36156765-55786932-5D5B-4C48-9EE3-B0C671BF3449Q36165689-B9C51079-41A3-4454-92B5-67C22203B465Q36221314-A151C815-EA9F-476E-A754-7F32CDAD2904Q36232324-E433B58F-F149-4E99-BA9E-9ED7D6502CF8
P2860
The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The Schizophrenia Patient Outc ...... reatment recommendations 2009.
@ast
The Schizophrenia Patient Outc ...... reatment recommendations 2009.
@en
type
label
The Schizophrenia Patient Outc ...... reatment recommendations 2009.
@ast
The Schizophrenia Patient Outc ...... reatment recommendations 2009.
@en
prefLabel
The Schizophrenia Patient Outc ...... reatment recommendations 2009.
@ast
The Schizophrenia Patient Outc ...... reatment recommendations 2009.
@en
P2093
P2860
P921
P356
P1476
The Schizophrenia Patient Outc ...... reatment recommendations 2009.
@en
P2093
Faith B Dickerson
Julie Kreyenbuhl
Lisa B Dixon
Robert W Buchanan
Schizophrenia Patient Outcomes Research Team (PORT)
P2860
P304
P356
10.1093/SCHBUL/SBP130
P407
P577
2009-12-02T00:00:00Z